Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We are delighted to announce that in recognition of the alliance between Oxford University and University College London, the Centre for the Acceleration of Medical Innovation (CAMI) is being renamed CASMI, the Centre for the Advancement of Sustainable Medical Innovation.

2012-12-05 CASMICASMI’s board will now be chaired jointly by Sir John Bell of Oxford and Sir John Tooke of UCL. This unique venture not only offers the Centre the support, infrastructure and international reputation of both institutions but also maximises engagement with academics at the forefront of their fields.

CASMI aims to address the issues that have lead to current failures in the translation of basic bioscience into affordable and widely adopted new treatments.

CASMI will continue the work on Adaptive Licensing (a new approach to enabling earlier access for patients to new medicines), the regulation of cell therapy and the future environment for stratified medicine. In 2013 we plan to extend into other key areas central to the effective generation, development, regulation and adoption of innovative medical technologies, and we welcome dialogue with supporters and collaborators on this future agenda.

See more on the CASMI website

Similar stories

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

AIMday in Women's Health - registration for academics now open

Events Innovation

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Women's Health.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.

New national study of long-term impacts of debilitating lung damage from COVID-19

Coronavirus COVID-19 General Research

A new national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. The study, launched with £2 million of funding from UK Research and Innovation (UKRI), aims to develop treatment strategies and prevent disability.